About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Molecular Cancer Therapeutics
›
Top Articles
Molecular Cancer Therapeutics
Oncology
6.1
(top 2%)
Impact Factor
6.5
(top 2%)
extended IF
177
(top 1%)
H-Index
5.8K
authors
5.3K
papers
265.7K
citations
5.8K
citing journals
114.6K
citing authors
Most Cited Articles of Molecular Cancer Therapeutics
Title
Year
Citations
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
2015
1.2K
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
2017
1.2K
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
2008
1.1K
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
2008
1K
The role of autophagy in cancer: therapeutic implications
2011
883
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
2011
847
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
2004
769
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo
2010
705
The role of the cyclin-dependent kinase inhibitor p21 in apoptosis
2002
610
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
2006
591
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer
2014
573
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
2007
547
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
2006
526
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin
2008
525
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo
2001
487
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
2007
471
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
2014
459
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
2009
444
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor
2012
432
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
2007
424
Platinum neurotoxicity pharmacogenetics
2009
417
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
2009
411
Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells
2005
402
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells
2002
400
Discovery and development of anticancer aptamers
2006
394
previous
2009
2010
2011
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.